Atea Pharmaceuticals, Inc. launches an IPO.

IPO of Atea Pharmaceuticals, Inc will take place on October 29, 2020. Atea is a clinical stage biopharmaceutical company that specializes in discovering, developing and commercializing anti-viral therapies to improve lives of patients suffering from life-threatening viral diseases. The company is currently focused on the development of orally available potent and selective nucleotide prodrugs for the treatment of life-threatening hard to cure viral infections such as severe acute respiratory syndrome, coronavirus 2 (SARS-CoV-2 virus that causes COVID-19) and hepatitis C virus.
The company’s estimated value after its IPO will be US$1.7 billion.

JP Morgan, Morgan Stanley, Evercore ISI and William Blair are listed bookrunners of the deal.